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BeOBJECTIVES This study assessed the ability of the dual-antiplatelet therapy (DAPT) score in stratifying ischemic and
bleeding risk in a contemporary percutaneous coronary intervention (PCI) population.
BACKGROUND The DAPT score is recommended by guidelines as a tool to stratify ischemic and bleeding risk. Its utility
in contemporary PCI is unknown.
METHODS The study studied patients in GLOBAL LEADERS (A Clinical Study Comparing Two Forms of Anti-platelet
Therapy After Stent Implantation) who were free of major ischemic and bleeding events and adhered to antiplatelet
strategy during the first year after PCI. The primary ischemic endpoint was the composite of myocardial infarction or stent
thrombosis. The primary bleeding endpoint was Bleeding Academic Research Consortium type 3 or 5. Outcomes from 12
to 24 months after PCI were compared according to the DAPT score.
RESULTS Of 11,289 patients that were event-free after the first year, 6,882 and 4,407 patients had low (<2) and high
($2) DAPT scores, respectively. Compared with a low DAPT score, patients with a high DAPT score had a higher rate of
the composites of myocardial infarction or stent thrombosis (0.70% vs. 1.55%; p < 0.0001). The rate of Bleeding Ac-
ademic Research Consortium type 3 or 5 bleeding was 0.54% and 0.30% in the low and high DAPT score groups,
respectively (p¼ 0.058). The effect of ticagrelor versus aspirin monotherapy on primary ischemic and bleeding endpoints
during the second year were no different among the 2 groups.
CONCLUSIONS The DAPT score can stratify ischemic but not bleeding risk in a contemporary PCI population during the
second year. The score did not provide additional value for selection of antiplatelet strategy beyond the first year.
(J Am Coll Cardiol Intv 2020;13:634–46) © 2020 the American College of Cardiology Foundation. Published by Elsevier.
All rights reserved.N 1936-8798/$36.00 https://doi.org/10.1016/j.jcin.2019.12.018
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AB BR E V I A T I O N S
AND ACRONYM S
ARD = absolute risk difference
ARDexperimental-reference =
absolute risk difference for
experimental minus reference
strategy
BARC = Bleeding Academic
Research Consortium
CI = confidence interval
DAPT = dual-antiplatelet
therapy
DES = drug-eluting stent
MI = myocardial infarction
PCI = percutaneous coronary
intervention
ST = stent thrombosis
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635T he dual-antiplatelet therapy (DAPT) scorewas developed to predict both ischemic andbleeding risk and thereby help select pa-
tients who would benefit most from extended DAPT
after the first year (1). Guidelines on DAPT have recog-
nized the DAPT score as a tool to stratify ischemic and
bleeding risk in patients treated with percutaneous
coronary intervention (PCI) (2,3).
The DAPT score has been validated in several
studies outside its derivation cohort; however, these
studies have yielded conflicting results, in which
some have confirmed its predictive value (4,5) and
some have not (6,7). Of note, most of the analyses
were from registries and substantial number of pa-
tients were treated with bare-metal stents or first-
generation drug-eluting stents (DES). It is well
known that using newer-generation DES mitigates
the ischemic risk of patients treated with PCI (8).
Hence, the performance of DAPT score in contempo-
rary PCI practice has not been fully evaluated and
needs further investigation.SEE PAGE 647In GLOBAL LEADERS (A Clinical Study Comparing
Two Forms of Anti-platelet Therapy After Stent Im-
plantation), 23-month ticagrelor monotherapy after
1-month DAPT (experimental strategy) was compared
with aspirin monotherapy after 12-month DAPT
(reference strategy) in all-comers patients treatedwithNational University of Ireland, Galway, Galway, Ireland; and the tInternation
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DES (9). In the second year after PCI, patients
in the experimental arm received ticagrelor
monotherapy while patients in the reference
arm received aspirin monotherapy.
In the present analysis, we used the pop-
ulation of the GLOBAL LEADERS study to
assess the ability of the DAPT score to stratify
ischemic and bleeding risk in the second year
after PCI. In addition, we assessed the effect
of ticagrelor monotherapy versus aspirin
monotherapy during the second year after
PCI in patients stratified by the DAPT score.
METHODS
STUDY POPULATION. The GLOBAL LEADERS
study (NCT01813435) was an investigator-initiated,
prospective randomized, multicenter, open-label
trial designed to evaluate 2 antiplatelet strategies
after PCI using bivalirudin and biolimus A9 eluting
stents in an all-comers population (9). In the first year
after PCI, patients in the experimental arm were
allocated to DAPT with aspirin 75 to 100 mg once daily
in combination with ticagrelor 90 mg twice daily for
1 month followed by monotherapy with ticagrelor
90 mg twice daily until 1 year, while patients in the
reference arm were allocated to DAPT with aspirin in
combination with either ticagrelor (acute coronaryal Centre for Circulatory Health, National Heart and
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636syndrome patients) or clopidogrel (stable coronary
artery disease patients) for 12 months. In the second
year, patients in the experimental arm continued
ticagrelor monotherapy while patients in the refer-
ence arm stopped their P2Y12 inhibitor and continued
with aspirin monotherapy.
The GLOBAL LEADERS study was approved by the
Institutional Review Board at each participating
institution. All patients provided written informed
consent. The study complied with the Declaration of
Helsinki and Good Clinical Practice. An independent
data and safety monitoring committee oversaw the
safety of all patients.
The GLOBAL LEADERS study enrolled 15,991 pa-
tients between July 2013 to November 2015 in an “all-
comers” design: no restriction regarding clinical pre-
sentation, complexity of the lesions, or number of
stents used. Because 23 patients withdrew consent
and requested data deletion from the database, a total
of 15,968 patients remained in the main analysis.
To be included in the current analysis patients
were required to: 1) have sufficient data to calculate
their DAPT score; and 2) have completed the first year
after the index PCI and be free of death, any stroke,
myocardial infarction (MI), revascularization, definite
or probable stent thrombosis (ST), and major bleeding
(Bleeding Academic Research Consortium [BARC]
type 3 or 5), together with adhering to their allocated
antiplatelet strategy. Patients who had missing vari-
ables for calculation of the DAPT score were excluded
from the analysis.
DAPT SCORE CALCULATION. The DAPT score was
developed to simultaneously predict the ischemic and
bleeding risk (1). The score ranges from –2 to 10 and
consists of 9 variables including age, cigarette smok-
ing, diabetes mellitus, MI at presentation, prior PCI or
prior MI, paclitaxel-eluting stent, stent
diameter <3 mm, congestive heart failure or left ven-
tricular ejection fraction<30%, and vein graft stent (1).
Patients were classified into 2 groups according to
predetermined cutoff points of the DAPT score; a high
score (DAPT score $2) indicated that the ischemic risk
reduction from extended DAPT outweighed the risk of
bleeding, whereas a low score (DAPT score <2) indi-
cated that the increased risk of bleeding from extended
DAPT outweighed the ischemic risk reduction.
OUTCOMES. As in the DAPT study, the primary
ischemic endpoint of the present study was a com-
posite of MI or definite or probable ST. The ST was
defined by the Academic Research Consortium defi-
nition (10). The primary bleeding endpoint was BARC
type 3 or 5 (11) while in the DAPT study moderate to
severe GUSTO (Global Use of Strategies to OpenCoronary Arteries) bleeding was used (12). Additional
endpoints were a composite of all-cause death, stroke
or MI, and a composite of BARC type 2, 3, or 5
bleeding. Individual components of the composite
endpoint were reported. The composite of all-cause
death or new Q-wave MI, which was a primary
endpoint of the main GLOBAL LEADERS study, and
net adverse clinical events, which was defined as a
composite of all-cause death, stroke, MI, or any
revascularization, was also reported. Outcomes were
analyzed in the study population from 12 months
after index PCI until death, the first occurrence of
the ischemic or bleeding events, loss to follow-up,
or 24 months after the index PCI, which corre-
sponds to the last follow-up visit in the GLOBAL
LEADERS study.
STATISTICAL ANALYSIS. The DAPT score was calcu-
lated in study patients using the clinical information
at the index PCI and the procedural information at the
index and staged PCI. Study patients were stratified
into 2 groups using the cutoff described in the DAPT
score derivation study: high ($2) or low (<2) DAPT
score. Clinical and angiographic characteristics were
compared between the 2 groups. Continuous variables
are expressed as mean  SD and were compared using
independent Student’s t-test. Categorical variables
are presented as count and proportion and were
compared using chi-square test. Outcomes were
compared between the 2 groups. The Kaplan-Meier
method was used to estimate the cumulative rates of
events and the log-rank test was performed to
examine the differences between the 2 groups. The
association between each level of DAPT score and the
risk of primary ischemic endpoint and primary
bleeding endpoint were assessed using the spline
function in the Cox regression analysis. Discrimina-
tion of ischemic and bleeding prediction models that
were used to derive the DAPT score was assessed
using Harrell’s C-statistics (Online Appendix).
The impact of ticagrelor monotherapy versus
aspirin monotherapy in the second year after PCI
among the high and low DAPT score groups was
assessed. We calculated the absolute risk difference
(ARD), which was based on a difference in Kaplan-
Meier estimate, and its 95% confidence interval (CI)
between experimental and reference strategy among
the DAPT score groups using the method described by
Altman et al. (13), and were compared using the Z-test
for interaction (14).
As a sensitivity analysis, we assessed the ability of
the DAPT score to stratify ischemic and bleeding
events during the second year in the reference and
experimental groups separately because the DAPT
scorewas originally developed in the cohort of patients
FIGURE 1 Flow Chart of the Study Population
The present study included patients in the GLOBAL LEADERS study who were free of major ischemic and bleeding events and adhered to their antiplatelet strategy
during the first year after percutaneous coronary intervention (PCI). Adherence to the allocated antiplatelet strategies was assessed at discharge, 1-, 3-, 6-, and 12-
month follow-up. Patients who were nonadherent at any time point during the first year after PCI and patients whom the information on adherence were missing were
excluded from the present analysis. BARC ¼ Bleeding Academic Research Consortium; DAPT ¼ dual-antiplatelet therapy; MI ¼ myocardial infarction.
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637who tolerated 12-month DAPT, and the duration of
DAPT in the GLOBAL LEADERS study was different
between the experimental and reference groups.
All analyses were performed on the intention-to-
treat population. A 2-sided p value <0.05 was
considered as statistically significant. All analyses
were performed in R version 3.4.2 (R Foundation for
Statistical Computing, Vienna, Austria).RESULTS
Of the 15,968 patients enrolled in the main analysis of
the GLOBAL LEADERS study, 11,430 patients did not
experience major ischemic and bleeding events and
were adherent to their antiplatelet strategy in the firstyear after their index PCI (Figure 1). Of the 11,430
patients, the DAPT score was available in 11,289
(98.8%) patients, in which 6,882 patients had a low
DAPT score and 4,407 patients had a high DAPT score
(Online Figure 1). Apart from the differences in vari-
ables used for the DAPT score calculation, the group
with a high DAPT score had a significantly higher
proportion of patients with prior CABG, multivessel
PCI, or more than 1 lesion treated, while the group
with a low DAPT score had a significantly higher
proportion of women and patients with hypertension,
renal impairment, and left main PCI (Table 1).
ISCHEMIC AND BLEEDING RISK STRATIFICATION BY
THE DAPT SCORE. The overall rate of MI or ST and
BARC type 3 or 5 bleeding in the studied population
TABLE 1 Clinical and Angiographic Characteristics of Low and High DAPT Score Groups
Low DAPT Score
(n ¼ 6,882)
High DAPT Score
(n ¼ 4,407) p Value
Age, yrs 67.48  9.65 58.56  8.21 <0.0001
Body mass index, kg/m2 27.95  4.33 28.60  4.85 <0.0001
Female 24.61 (1,694) 18.99 (837) <0.0001
Diabetes mellitus 16.61 (1,143) 36.03 (1,588) <0.0001
Insulin-treated 4.61 (317) 10.81 (474) <0.0001
Hypertension 74.84 (5,136) 70.07 (3,076) <0.0001
Hypercholesterolemia 70.03 (4,696) 70.18 (2,963) 0.8817
Current smoker 10.24 (705) 51.94 (2,289) <0.0001
Peripheral vascular disease 5.49 (375) 5.91 (258) 0.3687
Chronic obstructive pulmonary disease 4.46 (306) 4.09 (179) 0.3687
Previous major bleeding 0.47 (32) 0.68 (30) 0.1664
Impaired renal function* 14.36 (983) 8.89 (390) <0.0001
Prior stroke 2.37 (163) 2.27 (100) 0.7788
Previous myocardial infarction 16.45 (1,131) 31.21 (1,375) <0.0001
Previous percutaneous coronary intervention 25.15 (1,731) 41.48 (1,828) <0.0001
Previous coronary artery bypass grafting 4.64 (319) 6.06 (267) 0.001
Clinical presentation <0.0001
Stable coronary artery disease 63.14 (4,345) 38.98 (1,718)
Unstable angina 14.43 (993) 9.48 (418)
Non–ST-segment elevation myocardial infarction 14.05 (967) 30.91 (1,362)
ST-segment elevation myocardial infarction 8.38 (577) 20.63 (909)
Heart failure or left ventricular ejection fraction <30% 0.65 (45) 6.40 (282) <0.0001
Lesions treated 1.36  0.69 1.49  0.78 <0.0001
Lesions treated per patient <0.0001
1 72.92 (5,008) 64.70 (2,846)
2 20.21 (1,388) 24.82 (1,092)
3 or more 6.87 (472) 10.48 (461)
Left main PCI 2.68 (184) 2.09 (92) 0.0566
Right coronary artery PCI 36.23 (2,488) 38.01 (1,672) 0.0584
Left anterior descending artery PCI 53.57 (3,679) 47.65 (2,096) <0.0001
Left circumflex artery PCI 27.23 (1,870) 38.03 (1,673) <0.0001
Saphenous vein graft PCI 0.25 (17) 2.09 (92) <0.0001
Number of stent per patient 1.62  0.99 1.81  1.10 <0.0001
Multivessel PCI 19.57 (1,344) 25.05 (1,102) <0.0001
Bifurcation PCI 15.01 (1,031) 15.98 (703) 0.1725
Mean stent length, mm 24.18  12.46 25.50  13.04 <0.0001
Stent diameter <3 mm 38.45 (2,646) 65.49 (2,886) <0.0001
Values are mean  SD or % (n). *Defined as an estimated glomerular filtration rate of <60 ml/min/1.73 m2 based on the Modification of Diet in Renal Disease formula.
DAPT ¼ dual-antiplatelet therapy; PCI ¼ percutaneous coronary intervention.
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638were 1.03% and 0.44%, respectively. Compared with
the low DAPT score group, patients with a high DAPT
score had a higher rate of the composite of MI or ST
(1.55% vs. 0.70%; p < 0.0001) and all-cause death,
stroke, or MI (2.31% vs. 1.98%; p ¼ 0.0037) (Figure 2).
The rate of BARC type 3 or 5 bleeding was 0.54%
and 0.30% in the low and high DAPT score groups,
respectively (p ¼ 0.058). The rate of BARC type 2, 3, or
5 bleeding was 1.66% in the low DAPT score group,
whereas it was 1.21% in the high DAPT score group
(p ¼ 0.0574).There were no between-group differences in the
rates of all-cause mortality and any stroke (Table 2).
In the sensitivity analysis, the ability of the DAPT
score to stratifying ischemic and bleeding risk was not
different between patients in the experimental and
reference group and may not be affected by the
duration of DAPT during the first year (Online
Table 1).
The C-statistic of the ischemic prediction model of
the DAPT score for MI or ST was 0.64 (95% CI: 0.59 to
0.70), while the C-statistic of the bleeding prediction
TABLE 2 Outcomes From 12 to 24 Months According to DAPT Score Group
Overall Low DAPT Score High DAPT Score Log-Rank p Value
MI or definite/probable stent thrombosis 1.03 (116) 0.70 (48) 1.55 (68) <0.0001
MI 0.96 (108) 0.66 (45) 1.44 (63) <0.0001
Definite or probable stent thrombosis 0.23 (26) 0.15 (10) 0.37 (16) 0.0186
All-cause death/stroke/MI 2.31 (260) 1.98 (136) 2.82 (124) 0.0037
All-cause death or new Q-wave MI 1.51 (169) 1.48 (101) 1.55 (68) 0.7576
All-cause death 1.09 (123) 1.06 (73) 1.14 (50) 0.7146
New Q-wave MI 0.45 (50) 0.48 (32) 0.42 (18) 0.6537
Stroke 0.40 (45) 0.41 (28) 0.39 (17) 0.8619
BARC type 3 or 5 bleeding 0.44 (50) 0.54 (37) 0.30 (13) 0.0580
BARC type 2, 3, or 5 bleeding 1.48 (162) 1.66 (110) 1.21 (52) 0.0574
BARC type 5 bleeding 0.10 (11) 0.07 (5) 0.14 (6) 0.2925
BARC type 3 bleeding 0.40 (45) 0.50 (34) 0.25 (11) 0.0442
BARC type 2 bleeding 1.10 (120) 1.18 (78) 0.98 (42) 0.3273
Net clinical adverse events 4.96 (559) 4.66 (320) 5.43 (239) 0.063
Values shown are Kaplan-Meier estimates in % (n).
BARC ¼ Bleeding Academic Research Consortium; MI ¼ myocardial infarction.
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639model of the DAPT score for BARC type 3 or 5 bleeding
was 0.69 (95% CI: 0.62 to 0.76). The C-statistics were
similar to or higher than in the original validation
cohort of the DAPT score (Online Table 2).
The risk of MI or ST gradually rises as the DAPT
score increases (Central Illustration). In contrast, the
DAPT score had a U-shaped association with the risk
of BARC type 3 or 5 bleeding.
ANTIPLATELET STRATEGY IN THE SECOND YEAR
AFTER PCI AND DAPT SCORE. At the end of the
second year after PCI, compared with the reference
strategy, the experimental strategy was associated
with a lower rate of MI or ST (0.82% vs. 1.22%; log-
rank p ¼ 0.0376; ARD for experimental minus refer-
ence strategy [ARDexperimental-reference] –0.40; 95% CI:
–0.77% to –0.03%) and the composite of all-cause
mortality, stroke, or MI (1.92% vs. 2.65%; log-rank
p ¼ 0.0100; ARDexperimental-reference –0.73%; 95% CI:
–1.28% to –0.18%) (Figure 3, Online Table 3). The rate
of BARC type 3 or 5 bleeding was not different be-
tween the 2 antiplatelet strategies (0.54% vs. 0.36%;
log-rank p ¼ 0.1381; ARDexperimental-reference 0.19%;
95% CI: –0.06% to 0.44%), whereas the rate of BARC
type 2, 3 or 5 bleeding was higher in the experimental
strategy versus the reference strategy (1.80% vs.
1.19%; log-rank p ¼ 0.0080; ARDexperimental-reference
0.61%; 95% CI: 0.16 to 1.07).
The event rates at the end of the second year after
PCI, according to antiplatelet strategies and DAPT
score group, are shown in Table 3. In both the low and
high DAPT score groups, the experimental
strategy was associated with a reduction of MI or ST
(ARDexperimental-reference: low DAPT score –0.51%;95% CI: –0.89% to –0.12%; high DAPT score –0.25%;
95% CI: –0.98% to 0.48%; pinteraction ¼ 0.5425)
(Figure 4). The finding was similar when the com-
posite endpoint of all-cause mortality, stroke, or MI
was tested as an ischemic event (ARDexperimental-refer-
ence: low DAPT score –0.88%; 95% CI: –1.53% to
–0.23%; high DAPT score –0.51%; 95% CI: –1.49% to
0.46%; pinteraction ¼ 0.5362).
Compared with the reference strategy, the experi-
mental strategy was not associated with a signifi-
cantly higher rate of BARC type 3 or 5 bleeding in both
low and high DAPT score groups (ARDexperimental-
reference: low DAPT score 0.32%; 95% CI: –0.03% to
0.68%; high DAPT score –0.02%; 95% CI: –0.34% to
0.30%; pinteraction ¼ 0.1535). The experimental strat-
egy was associated with an excess of BARC type 2, 3,
or 5 bleeding regardless of DAPT score group
(ARDexperimental-reference: low DAPT score 0.66%;
95% CI: 0.04% to 1.28%; high DAPT score 0.55%;
95% CI: –0.11% to 1.21%; pinteraction ¼ 0.8181)
(Figure 4).
The event rates at the end of the second year after
PCI according to each level of the DAPT score and the
assigned antiplatelet strategy are shown in the Online
Table 4.
DISCUSSION
The main findings of the present study are the
following: 1) patients with a high DAPT score had
higher rate of MI or ST than did those with a low DAPT
score; 2) patients with a low DAPT score had a higher
rate of BARC type 3 or 5 bleeding than did patients
with a high DAPT score; however, the difference was
FIGURE 2 Ischemic and Bleeding Outcomes From 12 to 24 Months After PCI According to DAPT Score Group
Time-to-first event curves for the ischemic and bleeding outcomes from 12 to 24 months after PCI in the study population with low (blue line) and high (red line) DAPT
score. (A) MI or definite or probable stent thrombosis; (B) composite of all-cause death, stroke, or MI; (C) BARC type 3 or 5 bleeding; and (D) BARC type 2, 3 or 5
bleeding. Abbreviations as in Figure 1.
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free of the major events and were adherent to the
antiplatelet therapy during the first year after PCI, as
in the DAPT study, treatment with ticagrelor mono-
therapy during the second year was associated with a
lower rate of MI or ST and a similar rate of BARC type3 or 5 bleeding to aspirin monotherapy; and 4) the
effect of antiplatelet strategy on MI or ST and
bleeding during the second year after the index PCI
was not different among the low and high DAPT score
groups, as shown by a negative p value for
interaction.
CENTRAL ILLUSTRATION Association Between the DAPT Score and the Ischemic or
Bleeding Risk
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Smooth spline curves of the association between DAPT score and the risk of myocardial infarction or stent thrombosis (red line) and BARC 3
or 5 bleeding (blue line). Shading represents the area of 95% confidence interval.
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641RISK STRATIFICATION OF ISCHEMIA AND BLEEDING
BY DAPT SCORE. The focused update on DAPT in
coronary artery disease by the European Society of
Cardiology has recognized the DAPT score as a tool for
stratifying ischemia and bleeding risk. However, the
European Society of Cardiology guidelines have also
called for additional validation in less well-selected
populations, treated only with new-generation
DES (3).
The DAPT score has been tested in several different
populations with conflicting results. It effectively
stratified the ischemic and bleeding risk in a pooled
cohort of 3 studies enrolling Japanese patients
treated with DES (5) and in the ADAPT-DES (Assess-
ment of Dual AntiPlatelet Therapy with Drug-Eluting
Stents) all-comers registry (4). Conversely, it failed todifferentiate the ischemic and bleeding events in the
patients enrolled in the ISAR-SAFE (Intracoronary
Stenting and Antithrombotic Regimen: Safety And
EFficacy of Six Months Dual Antiplatelet Therapy
After Drug-Eluting Stenting) trial (6). Recently Ueda
et al. (7) validated the score in a large Swedish reg-
istry, concluding that it did not adequately stratify
bleeding risks, while its discrimination of ischemic
risk was poor. The findings from this study led to
questions about the score’s application in a real-
world population. Nevertheless, there are some
limitations to these studies which need to be
acknowledged (15). First, it may not be appropriate to
evaluate the DAPT score using the C-statistics for in-
dividual outcomes because the C-statistic is a unified
score integrating both ischemic and bleeding risks,
FIGURE 3 Ischemic and Bleeding Outcomes From 12 to 24 Months After PCI According to Antiplatelet Strategies
Time-to-first event curves for the ischemic and bleeding outcomes from 12 to 24 months after PCI in the patients with ticagrelor monotherapy (yellow line) and aspirin
monotherapy (blue line). (A) MI or definite or probable stent thrombosis; (B) composite of all-cause death, stroke, or MI; (C) BARC type 3 or 5 bleeding; and (D) BARC
type 2, 3, or 5 bleeding. Abbreviations as in Figure 1.
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642and its main purpose is to uncouple ischemia from
bleeding risk (15). Second, most of the validation co-
horts dated from the period when the new-generation
DES and potent P2Y12 inhibitor were not widely used.
In the present analysis, by using the DAPT score,
we could identify patients with a high DAPT scorewho had a 2-fold higher rate of MI or ST than did
patients with a low DAPT score. However, the score
could not identify groups of patients with significant
difference in the risk of bleeding during the second
year after PCI. The relatively low rate of bleeding
during the second year after PCI in the present study
TABLE 3 Outcomes From 12 to 24 Months by Antiplatelet Strategy According to DAPT Score Group
Low DAPT Score (DAPT Score <2) (n ¼ 6,882) High DAPT Score (DAPT Score $2) (n ¼ 4,407)
p for
Interaction
Experimental
Strategy
Reference
Strategy p Value ARD* (95% CI)
Experimental
Strategy
Reference
Strategy p Value ARD* (95% CI)
MI or definite/probable
stent thrombosis
0.43 (14) 0.94 (34) 0.0122 –0.51 (–0.89 to –0.12) 1.42 (30) 1.67 (38) 0.5089 –0.25 (–0.98 to 0.48) 0.5425
MI 0.37 (12) 0.91 (33) 0.0057 –0.54 (–0.91 to –0.17) 1.18 (25) 1.67 (38) 0.179 –0.49 (–1.19 to 0.21) 0.8945
Definite or probable
stent thrombosis
0.06 (2) 0.22 (8) 0.0852 –0.16 (–0.34 to 0.01) 0.38 (8) 0.35 (8) 0.8786 0.03 (–0.33 to 0.38) 0.3571
All-cause death/stroke/MI 1.51 (49) 2.39 (87) 0.0087 –0.88 (–1.53 to –0.23) 2.55 (54) 3.06 (70) 0.3068 –0.51 (–1.49 to 0.46) 0.5362
All-cause death or
new Q-wave MI
1.34 (43) 1.61 (58) 0.3413 –0.27 (–0.85 to 0.30) 1.52 (32) 1.58 (36) 0.8587 –0.07 (–0.80 to 0.67) 0.6606
All-cause death 0.83 (27) 1.27 (46) 0.0799 –0.43 (–0.91 to 0.04) 1.13 (24) 1.14 (26) 0.9888 0.00 (–0.63 to 0.62) 0.2843
New Q-wave MI 0.54 (17) 0.42 (15) 0.5059 0.12 (–0.22 to 0.45) 0.38 (8) 0.44 (10) 0.7538 –0.06 (–0.44 to 0.32) 0.4947
Stroke 0.37 (12) 0.44 (16) 0.6466 –0.07 (–0.37 to 0.23) 0.33 (7) 0.44 (10) 0.5679 –0.11 (–0.47 to 0.26) 0.8769
BARC type 3 or 5 bleeding 0.71 (23) 0.39 (14) 0.0672 0.32 (–0.03 to 0.68) 0.28 (6) 0.31 (7) 0.8867 –0.02 (–0.34 to 0.30) 0.1535
BARC type 2, 3, or 5 bleeding 2.00 (63) 1.35 (47) 0.0352 0.66 (0.04 to 1.28) 1.49 (31) 0.94 (21) 0.099 0.55 (–0.11 to 1.21) 0.8181
BARC type 5 bleeding 0.03 (1) 0.11 (4) 0.2236 –0.08 (–0.20 to 0.03) 0.19 (4) 0.09 (2) 0.3631 0.10 (–0.10 to 0.32) 0.1446
BARC type 3 bleeding 0.68 (22) 0.33 (12) 0.0402 0.35 (0.01 to 0.69) 0.19 (4) 0.31 (7) 0.435 –0.12 (–0.41 to 0.18) 0.0414
BARC type 2 bleeding 1.34 (42) 1.03 (36) 0.2456 0.30 (–0.22 to 0.83) 1.25 (26) 0.72 (16) 0.0747 0.54 (–0.06 to 1.13) 0.5678
Net clinical adverse events 4.01 (130) 5.23 (190) 0.0166 –1.22 (–2.21 to –0.23) 5.19 (110) 5.64 (129) 0.5161 –0.45 (–1.79 to 0.89) 0.3653
Values are Kaplan-Meier estimates in % (n) unless otherwise indicated. *ARD between experimental and reference strategy—a negative value represents absolute reduction of event with experimental
strategy while a positive value represents absolute increase of event with experimental strategy.
ARD ¼ absolute risk difference; CI ¼ confidence interval; other abbreviations as in Tables 1 and 2.
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643could be one of the explanations why the DAPT score
could not differentiate the risk of bleeding between
the 2 groups. In addition, the incidence of post-PCI
bleeding in the first year after PCI is usually higher
than in the second year or after (16). Therefore, these
findings emphasize the importance of early ischemic
and bleeding risk stratification and the need for de-
cision making with risk scores to select antiplatelet
strategies during the early period after PCI in indi-
vidual patients undergoing contemporary PCI.
The exploratory analysis using a DAPT score cutoff
of 1 was performed because the distribution of the
DAPT score in the present study was different from
that in the DAPT study (Online Figure 2) including
paclitaxel-eluting stents, which contributed sub-
stantially to the parameter of the DAPT score, and is
no longer used in the current practice. The cutoff of 1
may be better in differentiating the ischemic and
bleeding risk; however, this analysis is absolutely
exploratory and further studies are warranted (Online
Tables 5 and 6).
ANTIPLATELET STRATEGY BEYOND THE FIRST YEAR
AND DAPT SCORE. The DAPT study showed that, in
patients who were free from the major ischemic and
bleeding event in the first year after DES implantation
and were adherent to antiplatelet therapy, the
extension of DAPT beyond 1 year was superior to
aspirin monotherapy in reducing the risk of ST and
major adverse cardiovascular and cerebrovascularevents (12), however, this extension increased the
risk of bleeding. The design of the GLOBAL LEADERS
study was different from the DAPT study; however,
the experimental strategy was based on the same
principle that long-term intense platelet inhibition
may offer a protective effect against ischemic events,
in a similar fashion as in the extended DAPT, without
substantial increase in the risk of bleeding.
The concept of using P2Y12 inhibitor monotherapy,
instead of aspirin, to prevent ischemic events in pa-
tients with atherosclerotic cardiovascular disease is
not new and dates back to decades ago. The CAPRIE
(Clopidogrel versus Aspirin in Patients at Risk of
Ischemic Event) study showed that clopidogrel was
superior to aspirin monotherapy in reducing the rate
of the composite ischemic endpoint and was not
associated with increased bleeding risk (17). A single-
center study supported results of the CAPRIE study in
which clopidogrel monotherapy during the second
year after DES implantation was associated with a
reduction in ischemic events compared with aspirin
monotherapy, while the bleeding risk was similar
(18). However, the study was inherently limited by its
retrospective nature and the results from dedicative
randomized controlled trials in patients treated with
DES are needed.
The efficacy and safety of potent P2Y12 inhibitor
monotherapy during the first year after PCI was
tested in the TWILIGHT (Ticagrelor With Aspirin or
FIGURE 4 DAPT Score and Antiplatelet Strategy During the Second Year After PCI
Absolute risk difference between the experimental strategy (ticagrelor monotherapy) vs. the reference strategy (aspirin monotherapy) on the outcomes during the
second year after PCI among DAPT score group: a negative value represents absolute reduction of event with experimental strategy whereas a positive value rep-
resents absolute increase of event with experimental strategy. Abbreviations as in Figure 1.
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644Alone in High-Risk Patients After Coronary Inter-
vention) study (19). Ticagrelor monotherapy signifi-
cantly reduced the risk of bleeding, while it was
noninferior to ticagrelor plus aspirin in terms of
ischemic risk. To date, the benefit of potent P2Y12
inhibitor monotherapy beyond the first year after PCI
has not been established in the dedicated randomized
controlled trial. In the present exploratory analysis,
we have demonstrated that ticagrelor monotherapy
during the second year was associated with a lower
rate of MI or ST compared with aspirin monotherapy
in the patients who fulfilled the inclusion criteria of
the DAPT study. The rate of clinically relevant
bleeding (BARC type 2, 3, or 5 bleeding) in the group
allocated to ticagrelor monotherapy was higher than
that in the group of aspirin monotherapy; however,
the rate of major bleeding (BARC type 3 or 5 bleeding)was similar between the 2 groups. This finding is
supported by the in vitro study showing that aspirin
offers small effect on platelet inhibition in the pres-
ence of potent P2Y12 inhibitor, and clinically, adding
aspirin to the potent P2Y12 inhibitor may not provide
additional ischemic protection but may increase the
risk of bleeding in patients (20).
The effect of ticagrelor monotherapy versus aspirin
monotherapy was not different among the low and
high DAPT score groups, as indicated by a negative
interaction test. Inevitably, this analysis was a post
hoc exploration and may suffer from inadequate po-
wer to detect a difference. Nevertheless, the concept
of long-term platelet inhibition with potent anti-
platelet regimens in selected patients after PCI who
had ischemic risk outweighs bleeding risk warrants
further investigation.
PERSPECTIVES
WHAT IS KNOWN? The DAPT score is recommended by
guidelines as a tool to stratify ischemic and bleeding risk beyond
the first year after PCI, and the score may identify patients who
would benefit from long-term potent P2Y12 inhibitor.
WHAT IS NEW? The DAPT score can stratify ischemic but not
bleeding risk beyond the first year after contemporary PCI.
Compared with aspirin monotherapy, ticagrelor monotherapy
during the second year after PCI may be associated with a
reduction in the risk of ischemic events without an increase in the
risk of major bleeding.
WHAT IS NEXT? The concept of long-term platelet inhibition
with potent antiplatelet regimens in selected patients after PCI
who had ischemic risk outweighs bleeding risk warrants further
investigation.
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645STUDY LIMITATIONS. First, the present study is a
post hoc analysis in a selected population in the
GLOBAL LEADERS study. Therefore, the results
should be interpreted with caution and considered as
hypothesis-generating. Second, in the present study,
DAPT score was calculated using clinical information
at the index PCI; hence, some variables such as ciga-
rette smoking or diabetic status could have changed
or developed during the first year after PCI. Third, the
event rates in the present study, even after adjusting
for the different period of follow-up, were relatively
low compared with those in the DAPT study. Hence,
the results were at risk for type II error to demon-
strate significant differences between 2 comparisons.
Fourth, the difference in the bleeding definition be-
tween the DAPT study (GUSTO definition) and the
GLOBAL LEADERS study (BARC definition) may affect
the assessment of the DAPT score performance.
However, the rates of moderate or severe GUSTO
bleeding and the BARC type 3 and 5 bleeding were
comparable in the DAPT study (12). Fifth, because the
DAPT regimens in the first year were different be-
tween the experimental and reference strategy, the
number of patients who were excluded because of the
events during the first year was different between the
2 groups. This difference caused some imbalance in
patient characteristics between the 2 groups and
might influence the results on the effect of anti-
platelet strategies between the 2 DAPT score groups
(Online Tables 7 to 9).
Finally, there was no central and global adjudica-
tion for serious adverse events in this investigator-
driven trial, and the endpoints were site-reported.
Nevertheless, there was regular monitoring and on-
site visits for consistency of event definitions and
underreport of the events.CONCLUSIONS
The DAPT score can stratify ischemic but not bleeding
risk during the second year in the GLOBAL LEADERS
study population. The effect of antiplatelet strategy
during the second year after PCI was not different
among the low and high DAPT score groups. The
value of the score to select the optimal antiplatelet
regimen during the second year after PCI warrants
further investigation.
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